Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders

Patent metadata

Field	Value
Publication number	US-10314893-B2
Application number	US-201615030377-A
Country	US
Kind code	B2
Filing date	Apr 18, 2016
Priority date	Oct 18, 2013
Publication date	Jun 11, 2019
Grant date	Jun 11, 2019

Abstract

Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.
Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.

First claim

What is claimed is:

1. A method for the treatment of pulmonary hypertension comprising oral administration of an effective amount of a composition comprising lyophilized plant material comprising
i) a fusion protein comprising angiotensin-converting enzyme 2 (ACE-2) and cholera non toxic B subunit (CTB); or
ii) a fusion protein comprising angiotensin-(1-7) (Ang-(1-7)), and CTB or
i) and ii) in combination to a patient in need thereof, said composition exerting a cardioprotective effect comprising at least one of improved right heart function, decreased pulmonary vessel wall thickness, and a lack of altered basal system blood pressure, said method optionally comprising assessing said effects after administration of said composition.

2. The method of claim 1 , said composition comprising lyophilized plant material obtained from a homoplasmic plant expressing said fusion protein comprising ACE-2 and CTB.

3. The method of claim 1 , said composition comprising lyophilized plant material obtained from a homoplasmic plant expressing said fusion protein comprising Ang-(1-7) and CTB.

4. The method of claim 3 , said composition further comprising lyophilized plant material obtained from a homoplasmic plant expressing said fusion protein comprising ACE-2 and CTB.

5. The method of claim 2 , wherein said homoplasmic plant is lettuce and said fusion protein comprising ACE-2 and CTB is encoded by a sequence comprising SEQ ID NO: 24 or SEQ ID NO: 26.

6. The method of claim 3 , said fusion protein comprising Ang-(1-7) and CTB further comprising a hinge peptide and/or a furin cleavage site between said Ang-(1-7) and said CTB.

Assignees

• Univ Pennsylvania
• Univ Florida
• Univ Florida

Inventors

• Daniell Henry
• Li Qiuhong
• Raizada Mohan K

Classifications

• C12N15/8214

  Plastid transformation · CPC title

• C12N15/8257

  for the production of primary gene products, e.g. pharmaceutical products, interferon · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• C07K2319/55

  containing a fusion with a toxin, e.g. diphteria toxin · CPC title

• C12Y304/15001

  Peptidyl-dipeptidase A (3.4.15.1) · CPC title